Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hamps Bio's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.26.
Hamps Bio's long-term debt to total assets ratio
increased
from Mar. 2025 (0.16) to Mar. 2026 (0.26).
It may suggest that Hamps Bio is progressively becoming more dependent on debt to grow their business.
Hamps Bio (BOM:544312) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Hamps Bio LT-Debt-to-Total-Asset Related Terms
Hamps Bio LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Hamps Bio's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio (BOM:544312) has a LT-Debt-to-Total-Asset of 0.26 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hamps Bio and its competitors.
Is Hamps Bio's LT-Debt-to-Total-Asset too high?
Hamps Bio's current LT-Debt-to-Total-Asset is 0.26. Overall, Hamps Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's LT-Debt-to-Total-Asset compare to competitors?
Hamps Bio's LT-Debt-to-Total-Asset of 0.26 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?
A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hamps Bio and its competitors. Hamps Bio's current LT-Debt-to-Total-Asset is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current LT-Debt-to-Total-Asset of 0.26. The current LT-Debt-to-Total-Asset is 0.26. Hamps Bio's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current LT-Debt-to-Total-Asset is 0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
12GF Score
Get the complete analysis for BOM:544312
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
